| pubmed-article:1418730 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0007004 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0376659 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0041361 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C1527177 | lld:lifeskim |
| pubmed-article:1418730 | lifeskim:mentions | umls-concept:C0441513 | lld:lifeskim |
| pubmed-article:1418730 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1418730 | pubmed:dateCreated | 1992-12-1 | lld:pubmed |
| pubmed-article:1418730 | pubmed:abstractText | Tumor vaccinology is as old as immunological thought and as young as our rapidly evolving understanding of antigen processing and presentation. The recent availability of carbohydrate and peptide tumor antigens suitable for vaccine construction, conjugate and recombinant vector technologies capable of augmenting helper and cytotoxic T cell activity and potent new immunological adjuvants have combined to produce considerable optimism for the future of tumor vaccines. | lld:pubmed |
| pubmed-article:1418730 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1418730 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1418730 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1418730 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1418730 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1418730 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1418730 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1418730 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1418730 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1418730 | pubmed:issn | 0952-7915 | lld:pubmed |
| pubmed-article:1418730 | pubmed:author | pubmed-author:LivingstonP... | lld:pubmed |
| pubmed-article:1418730 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1418730 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:1418730 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1418730 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1418730 | pubmed:pagination | 624-9 | lld:pubmed |
| pubmed-article:1418730 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:meshHeading | pubmed-meshheading:1418730-... | lld:pubmed |
| pubmed-article:1418730 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1418730 | pubmed:articleTitle | Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. | lld:pubmed |
| pubmed-article:1418730 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021. | lld:pubmed |
| pubmed-article:1418730 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1418730 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1418730 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1418730 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1418730 | lld:pubmed |
